8-K
filed June 28, 2023, 7:59 PM ET
ticker UTHR
CIK 0001082554
other material
confidence high
sentiment neutral
materiality 0.40
United Therapeutics shareholders approve stock plan amendment increasing shares by 1M, extend plan to 2033
UNITED THERAPEUTICS Corp
- Shareholders approved amendment to 2015 Stock Incentive Plan, increasing authorized shares by 1,000,000 and extending plan to April 20, 2033.
- All 12 director nominees elected, with votes for ranging from 33.8M to 39.6M; broker non-votes of 1.4M on each.
- Advisory vote on executive compensation approved: 38.7M for, 1.2M against, 220.6K abstain.
- Frequency of future say-on-pay votes set at 1 year (39.1M votes).
- Ratification of Ernst & Young as independent auditor approved: 40.7M for, 748.9K against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNITED THERAPEUTICS Corp shareholders approved Election of directors at the 2023-06-26 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
1. Election of directors, each to serve a term of one year: Nominee Votes For Votes Against Abstentions Broker Non-Votes Christopher Causey 35,053,530 5,031,361 12,874 1,386,890 Raymond Dwek 36,922,017 3,160,178 15,570 1,386,890 Richard Giltner 38,428,288 1,653,830 15,647 1,386,890 Katherine Klein 38,338,087 1,747,250 12,428 1,386,890 Ray Kurzweil 37,519,403 2,565,464 12,898 1,386,890 Linda Maxwell 39,551,557 530,644 15,564 1,386,890 Nilda Mesa 37,815,938 2,261,956 19,871 1,386,890 Judy Olian 38,469,361 1,613,228 15,176 1,386,890 Christopher Patusky 36,100,963 3,983,909 12,893 1,386,890 Martine Rothblatt 38,170,992 1,905,182 21,591 1,386,890 Louis Sullivan 36,872,530 3,208,848 16,387 1,386,890 Tommy Thompson 33,785,847 6,295,860 16,058 1,386,890
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNITED THERAPEUTICS Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023 at the 2023-06-26 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
5. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023: Votes for: 40,725,112 Votes against: 748,871 Abstentions: 10,672 Broker non-votes: —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNITED THERAPEUTICS Corp shareholders approved Advisory resolution to approve executive compensation at the 2023-06-26 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
2. An advisory resolution to approve executive compensation: Votes for: 38,688,651 Votes against: 1,188,503 Abstentions: 220,611 Broker non-votes: 1,386,890
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNITED THERAPEUTICS Corp shareholders approved Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan at the 2023-06-26 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-26
Exact text from the filing
4. Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan: Votes for: 34,925,060 Votes against: 5,085,389 Abstentions: 87,316 Broker non-votes: 1,386,890
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UNITED THERAPEUTICS Corp shareholders voted on Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-26 meeting.
- Proposal
- say on pay frequency
- Meeting
- 2023-06-26
Exact text from the filing
3. An advisory vote on the frequency of future advisory votes on executive compensation: One year: 39,071,056 Two years: 4,467 Three years 956,691 Abstentions: 65,551 Broker non-votes: 1,386,890
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.